|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on December 27, 2002; DOI 10.1182/blood-2002-07-2283.
NEOPLASIA
From the Clinical Research Division, Fred Hutchinson
Cancer Research Center, Seattle, WA; the Department of Medicine,
University of Washington, Seattle; and the Department of Pathology,
University of New Mexico and UNM Cancer Center, Albuquerque.
The mevalonate pathway produces many critical substances in cells,
including sterols essential for membrane structure and isoprenoids
vital to the function of many membrane proteins.
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a
rate-limiting enzyme in the mevalonate pathway. Because cholesterol is
a product of this pathway, HMG-CoA reductase inhibitors (statins) are
used to treat hypercholesterolemia. Statins are also toxic to several
malignancies, including acute myeloid leukemia (AML). Although this
toxicity has been attributed to the inhibition of Ras/Rho
isoprenylation, we have previously shown that statin toxicity in
primary AML cells (AMLs) does not correlate with Ras isoprenylation or
with activating Ras mutations. In other studies, we
have shown that hypoxic and oxidant injuries induce cholesterol
increments in renal tubule cells and that statins sensitize
these cells to injury by blocking protective cholesterol responses. We now demonstrate that exposing particular AMLs to radiochemotherapy induces much greater cellular cholesterol increments than those seen in similarly treated normal bone marrow. Treatment of
these AMLs with mevastatin or zaragozic acid (which inhibits cholesterol synthesis but not isoprenoid synthesis) attenuates the
cholesterol increments and sensitizes cells to radiochemotherapy. The
extent of toxicity is affected by the availability of extracellular lipoproteins, further suggesting that cellular cholesterol is critical
to cell survival in particular AMLs. Because zaragozic acid does not
inhibit isoprenoid synthesis, these data suggest that cholesterol
modulation is an important mechanism whereby statins exert toxic
effects on some AMLs and that cholesterol modulators may improve
therapeutic ratios in AML by impacting cholesterol-dependent cytoresistance.
(Blood. 2003;101:3628-3634) Cholesterol is a biosynthetic end product of
the mevalonate pathway in eukaryotes, as are many other compounds,
including steroid hormones, vitamin D, dolichol, and ubiquinone. In
higher animals, cells can also obtain dietary cholesterol from plasma low-density lipoprotein (LDL) through receptor-mediated endocytosis and
lysosomal processing. Cells control the importation and biosynthesis of
cholesterol by feedback regulation of LDL receptors and of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme of the mevalonate pathway (reviewed by Goldstein and Brown1). When LDL levels are high, HMG-CoA reductase
activity in normal cells is reduced by as much as 90%, and cholesterol synthesis is effectively blocked.1 When cellular sterol
levels are high, or when proliferation and the need for cholesterol are low, LDL receptor transcription is repressed. On the other hand, when
acutely deprived of cholesterol, normal cells increase sterol synthesis
and LDL import. Numerous studies have demonstrated that abnormally
elevated levels of serum cholesterol contribute to atherosclerosis and
coronary artery disease, and HMG-CoA reductase inhibitors
("statins"), including pravastatin, simvastatin, lovastatin, and
atorvastatin, are widely used clinically to treat patients with
hypercholesterolemia.2
Cholesterol metabolism is dysregulated in many malignancies,
including myeloid leukemias. Freshly isolated acute myeloid leukemia (AML) and chronic myelogenous leukemia cells show more LDL processing than normal blood cells,3,4 and cholesterol levels in
leukemia cells often do not exhibit feedback repression in high-sterol media.4 Rapidly proliferating tumor cells presumably
require cholesterol for new membrane synthesis. However, high cellular cholesterol may also improve leukemia cell survival and impart relative
resistance to therapy. Compared with their parental cell lines,
drug-resistant myeloid leukemia cell lines show higher HMG-CoA
reductase levels,5 and drug-resistant lymphoid
leukemia cell lines have increased cholesterol and phospholipid
levels,6 suggesting that acute cholesterol responses may
contribute to drug resistance. Consistent with a critical role(s) for
the mevalonate pathway in tumor cell growth and survival, and with the
rate-limiting role of HMG-CoA reductase in this synthetic pathway,
statins have in vivo or in vitro activity against human head and neck,
pancreatic, and central nervous system tumors and against human myeloid
leukemia cells in xenograft models.7-11 A phase 1 clinical
study showed that serum lovastatin concentrations of up to 3.9 µM
could be achieved without significant tissue toxicity.12
Dimitroulakos et al showed that similar doses of lovastatin were
selectively toxic to AML cell lines and primary AML cell samples but
not to acute lymphocytic leukemias.13 We have shown that
most AMLs are sensitive to mevastatin as a single agent and in drug
combinations,14 further suggesting that statins might be
effective in anti-AML regimens.
Plasma membrane localization is essential to the function of many
proteins that impact cellular proliferation and/or survival. Because
the membrane localization of many of these signaling proteins requires
mevalonate-derived farnesyl or geranylgeranyl isoprenoid modifications,
the antitumor effects of statins have been assumed to be primarily due
to their blockade of isoprenylation. For example, Ras proteins are
activated by mutation and/or overexpression in a large fraction of
human tumors, including myeloid leukemias, thereby contributing to
reduced apoptosis, increased cell proliferation, and poor clinical
outcomes.15,16 Isoprenylation of Ras and other similarly
modified membrane proteins is specifically mediated by farnesyl-protein
and geranylgeranyl-protein transferases, and farnesyl-protein
transferase inhibitors can, like statins, induce tumor regression in
mice carrying mammary or lymphoid tumors overexpressing H- or
N-Ras.17-19 However, we have recently shown that statin
toxicity in primary AMLs is variable and not consistently higher in
samples with Ras overexpression or with Ras activated by "hotspot"
mutations.14 Others have argued that non-Ras
geranylgeranylated proteins are important statin
effectors.20 However, our cell line data show that
dependence on geranylgeranylation as well as farnesylation can be
dissociated from statin sensitivity in AMLs.14 In
addition, statin concentrations necessary to inhibit specific protein
isoprenylation are 100- to 500-fold higher than those required to
inhibit cholesterol synthesis in the same cells21 and are
higher than the concentrations that are toxic to AML
cells.14
In other studies, we have shown that acute renal injuries caused by
ischemia, oxidant damage, and ureteral obstruction increase renal
cortical cholesterol content.22 Cholesterol levels are similarly increased in cultured human HK-2 proximal renal tubule cells
subjected to iron-mediated oxidant stress.22 In these kidney cell models, increased cellular cholesterol makes cells highly
resistant to subsequent damage, producing a state known as "acquired
cytoresistance." Reducing cellular cholesterol levels pharmacologically blocks acquisition of cytoresistance and can generate
profound mitochondrial dysfunction and death in kidney cells, further
demonstrating the critical role of cholesterol in renal cell
homeostasis.22
Given these observations, we have undertaken the present study to
assess the potential role of cellular cholesterol in protecting AMLs
against radiochemotherapeutic insults. Toward this end, several AML
cell lines and cryopreserved primary AML cell samples were treated with
chemotherapy, radiation, or cholesterol modulators, alone or in
combination. The impacts of these treatments on cell survival and
cellular cholesterol content were then assessed.
Cell culture
Use of the human bone marrow samples (normal and AML) was approved by
the institutional review boards of the Fred Hutchinson Cancer Research
Center, CCG, and SWOG.
Flow cytometry assays
Cholesterol measurements Cellular cholesterol levels were measured by 1 of 2 techniques:Gas chromatography. As we previously described,22,28 lipids from a suspension of 107 cells were extracted in chloroform-methanol (1:2) and dried under nitrogen. After reconstitution in hexane, samples were transferred to glass tubes containing an internal standard solution (stigmasterol, 100 µg/mL in ethyl acetate [EtOAc]; Sigma), dried under nitrogen, and reconstituted in 100 µL bis-(trimethylsilyl)trifluoroacetamide (BSTFA; Sigma) (25% vol/vol EtOAc). These samples were then sealed in an injection vial and heated for 1 hour at 60°C. After completion of BSTFA derivatization, samples were applied to a Hewlett Packard 5890 Series II gas chromatograph fitted with a flame ionization detector and a 30 m × 0.32 mm DB-5 (0.25 µm) column (J&W Scientific, Folsom, CA). The initial temperature (100°C) was maintained for 3 minutes, after which it was increased by 40°C per minute to 290°C and thereafter by 5°C per minute to 300°C for 5 minutes. Cholesterol ethers were quantitated after elution from the gas chromatograph at 12.5 minutes. Amplex Red assay (Molecular Probes, Eugene, OR). This is a fluorometric technique that relies on the oxidation of cholesterol into a ketone and hydrogen peroxide. The hydrogen peroxide reacts stoichiometrically with the Amplex Red reagent (10-acetyl-3,7-dihydroxyphenoxazine) in the presence of horseradish peroxidase to form the fluorescent compound resorufin. To perform this assay, cell samples were initially counted by microscopy via the trypan blue exclusion method and then washed once in PBS. The cells were then resuspended in the Amplex Red reaction buffer (0.1 M potassium phosphate, 0.05 M NaCl, 5 mM cholic acid, 0.1% Triton X-100, pH 7.4) at a concentration of 2000/µL and vortexed; both viable and nonviable cells were included. After 50-µL aliquots of each of the resulting cell lysates were pipetted into a 96-well tissue culture plate (Falcon/Becton Dickinson, Franklin Lakes, NJ), a 50-µL aliquot of an Amplex Red working solution (300 µM Amplex Red reagent, 2 U/mL horseradish peroxidase, 2 U/mL cholesterol oxidase, and 0.2 U/mL cholesterol esterase) was added to each well. The plate was then incubated for 90 minutes at 37°C, protected from light. Fluorescence was subsequently measured on a CytoFluor II fluorescent plate reader (PerSeptive Biosystems, Framingham, MA) using an excitation wavelength of 530 nm and an emission wavelength of 590 nm. A cholesterol standard curve was also determined for each plate using a cholesterol calibrator (Sigma) diluted at various concentrations in Amplex Red reaction buffer in lieu of cell lysates. Calculations and statistics All values are presented as the mean ± 1 standard error of the mean. Statistical comparisons were performed with either the paired or unpaired Student t test, as appropriate.
Cholesterol levels can be measured in AML cells To study cellular cholesterol as a drug-resistance effector and cholesterol modulation as a rational antileukemia strategy, we needed the ability to determine cholesterol levels in different AML cell lines and in primary AML cell samples. To that end, we first measured cholesterol using gas chromatography, as we previously described.22,28 NB4 cells grown in serum-containing media showed somewhat higher cholesterol levels (78 ± 12 nmol/10 million cells, equivalent to 7.8 nmol/106 cells) than HL60 cells (57 ± 10 nmol/10 million cells, or 5.7 nmol per 106 cells) when cholesterol was quantified in equal numbers of viable cells. However, because these gas chromatographic assays require 10 million cells for each measurement, they are not well suited for measuring the impact of different experimental variables on cellular cholesterol levels, especially in size-limited primary AML cell samples. Therefore, we adapted the Amplex Red assay, which measures the release of hydrogen peroxide upon cholesterol oxidation and can be used with much smaller cell numbers in a 96-well plate format. Having demonstrated the feasibility and reproducibility of the Amplex Red assay (Figure 1A-B), we used it to measure total cholesterol levels in AML cell lines. Consistent with data derived from gas chromatography assays, Amplex Red assays of the cholesterol content of 105 cells in 100-µL volumes were consistently higher in NB4 cells (4.4 ± 0.2 µM in 100 µL assay, equivalent to 4.4 ± 0.2 nmol/106 cells) than in HL60 cells (3.6 ± 0.4 nmol/106 cells, P = .12 relative to NB4) or KG1a cells (3.3 ± 0.2 nmol/106 cells, P = .001) (Figure 1C). Constitutive cholesterol levels in 29 primary AML cell samples were also determined, ranging from 1.0 to 9.9 nmol/106 cells (mean 2.7 ± 0.3 nmol/106 cells) (Table 1). Therefore, cellular cholesterol levels can be measured using a relatively small number of cells per assay, and these measures show that constitutive levels in primary AML cell samples are quite variable.
Cholesterol levels are increased in certain AMLs by treatment with therapeutic agents We previously showed that sublethal hypoxia and oxidant injuries in kidney cells induce cellular cholesterol increments and that mevastatin cotreatments both block cholesterol increments and increase the toxicity of these injuries.28 To determine whether AML cells also acutely increase cellular cholesterol after exposure to cytotoxic substances, we examined the effects of 3 leukemia-relevant therapeutic agents on cellular cholesterol levels. We treated NB4, HL60, KG1a, and ML-1 cells for 24 hours with equitoxic doses of ARA-C, DNR, or -irradiation that produced no more than 10% cell death as
measured by trypan blue uptake. Cellular cholesterol levels in ML-1
were not affected by any of these treatments (data not shown). However,
we found significantly increased cholesterol levels in treated NB4
cells (treated with radiation, P = .002 compared with
untreated cells; DNR P = .03; ARA-C P = .003)
and in treated HL60 cells (radiation P = .0004; DNR
P = .05; ARA-C P = .03) (Figure
2). Treated KG1a cells showed cholesterol
increments that were marginally significant for radiation
(P = .045) but not for DNR (P = .3) or ARA-C
(P = .25).
We also examined the effects of 24-hour chemotherapy exposures on the cellular cholesterol content of primary AML cells (Table 1). Overall, treatment with daunorubicin resulted in significantly higher levels of cellular cholesterol in primary AML cell samples (120% ± 5% relative to constitutive cholesterol levels in the corresponding untreated cells) compared with similarly treated normal bone marrow cell samples (93% ± 3% relative to constitutive cholesterol levels in the corresponding untreated cells, P < .006). A trend toward higher levels of cellular cholesterol after cytarabine treatment was also seen for primary AML cell samples compared with similarly treated normal bone marrow cell samples (123% ± 6% versus 102% ± 9%, P = .09). Because cell line data (Figure 2) indicated that only some AML cells substantially increase cellular cholesterol after treatment with particular therapeutic agents, we also analyzed separately the data from primary AML cell samples that increased cellular cholesterol content after chemotherapy (18 of 28 daunorubicin-treated samples; 16 of 27 cytarabine-treated samples). This analysis demonstrated a significant effect in relative cholesterol change in responsive AMLs compared with that seen in similarly treated normal bone marrow cell samples (132% ± 6% versus 93% ± 3% for daunorubicin-treated cells, P < .0002; 139% ± 8% versus 102% ± 9% for cytarabine-treated cells, P < .008). In summary, the data suggest that some primary AML cell samples, as well as some AML cell lines, do acutely (ie, within 24 hours) mount substantial increases in cellular cholesterol content after exposure to relevant therapeutic modalities. Statin sensitivity in AML cell lines is associated with sensitivity to other cholesterol-modulating treatments In light of prior studies documenting the sensitivity of some AMLs to statins13,14 and our current studies showing that certain AML primary cell samples and cell lines increase cellular cholesterol after exposure to therapeutic agents, we hypothesized that particular AMLs depend critically on cholesterol for their survival. To test this prediction, we evaluated the potential toxicity of several cholesterol-modulating agents: (1) mevastatin, which inhibits HMG-CoA reductase29; (2) cholesterol oxidase (CO), which oxidizes free cholesterol30; and (3) cholesterol esterase (CE), which cleaves cholesterol esters.30 As shown in Figure 3A, NB4 cells were significantly sensitive to mevastatin at 5 µg/mL (P = .008 versus untreated cells), 25 µg/mL (P = .005), and 50 µg/mL (P < .001) in apoptosis assays that measure the accumulation of cells with less than a 2N/G1 (ie, sub-G1) DNA content. These mevastatin-sensitive NB4 cells also demonstrated increased apoptosis after treatment with 0.1 µM CE and 0.1 µM CO (P = .004 and P = .055, respectively) (Figure 3B). HL60 cells showed intermediate sensitivity to 50 µg/mL mevastatin (P = .006) and showed increased apoptosis after CE and CO treatments (Figure 3B), although these increases were not statistically significant. On the other hand, KG1a cells were relatively insensitive to CE, CO, and mevastatin (Figure 3B). Therefore, statin sensitivity in AML cell lines is associated with sensitivity to other cholesterol-modulating agents.
Cholesterol-reducing agents are toxic as single agents and can sensitize particular AMLs to treatments with therapeutic modalities To further address whether blocking adaptive cholesterol responses to cytotoxic agents results in the sensitization of individual AMLs that can mount such responses, we examined the effects of zaragozic acid A (ZGA), which inhibits squalene synthase at the final branch point of the cholesterol synthesis pathway,31,32 on NB4 cell survival and cholesterol levels (Figure 4). Twenty-four-hour treatments with ZGA as a single agent at 64 µM or 256 µM minimally affected cell death (assessed by trypan blue uptake [TB+]) and cholesterol levels in NB4 cells (Figure 4A-B). ZGA at 256 µM, however, induced more than 80% toxicity within 60 hours, while ZGA at 64 µM induced more than 80% toxicity after 120-hour treatments (Figure 4C). ZGA (256 µM) significantly increased the toxicities of cytarabine (0.5 µM) or-radiation (390 cGy) in NB4 cells after 24-hour cotreatments, relative to the
toxicities of cytarabine (P < .001) or radiation
(P = .032) alone (Figure 4A). Increased toxicities were
associated with significant decreases in the cellular cholesterol
content of cells cotreated for 24 hours with both ZGA (256 µM) and
either cytarabine or radiation, as compared with levels seen in cells
receiving either cytarabine (P < .001) or radiation
(P = .002) alone (Figure 4B). These data, in conjunction with the data presented in Figure 2, suggest that some AML cell lines,
including NB4 cells, acutely augment cellular cholesterol after
exposure to cytotoxic agents such as chemotherapy and radiation and
that attenuation of these adaptive cholesterol responses results in
decreased AML cell survival.
To further address whether cellular cholesterol levels can be
critical to AML cell survival, we tested whether the effects of
cholesterol synthesis inhibition on cell death and cellular cholesterol
can be modulated by the availability of exogenous cholesterol in the
cell culture environment. Because intracellular cholesterol levels are
established not only by HMG-CoA reductase- and squalene
synthase-regulated de novo synthesis, but also by receptor-mediated
import of ambient cholesterol contained in LDL particles,1
we examined the effects of mevastatin and ZGA on NB4 cells cultured in
a serum-depleted (and therefore cholesterol-depleted) medium. We found
that both mevastatin (data not shown) and ZGA (Figure
5A) produced larger cellular cholesterol
decrements in NB4 cells cultured for 24 hours under serum-depleted
conditions compared with NB4 cells cultured in a
cholesterol-containing, serum-replete medium. ZGA at 256 µM was also
substantially more toxic to NB4 cells (Figure 5B versus 4A) and HL60
cells (data not shown) cultured under serum-depleted conditions
compared with those cultured in a serum-replete medium. In addition,
growth in serum-depleted culture medium sensitized NB4 and HL60 cells to mevastatin toxicity (data not shown).
Because serum contains various growth-regulating substances in addition to cholesterol, the enhanced toxicity of ZGA and mevastatin in serum-deprived NB4 cells might have resulted from the depletion of one or more of these other substances rather than from depletion of cholesterol. To demonstrate that the additional toxicity of cholesterol synthesis blockade under serum-depleted conditions arose from critical cellular cholesterol reductions rather than depletion of serum growth factors, for instance, we examined the impact of adding cholesterol, in the form of commercially available LDL, to cells in serum-depleted culture media. LDL addition measurably increased cellular cholesterol in serum-depleted NB4 cells (Figure 5A) and reversed the profound toxicity of 256 µM ZGA (P = .003; Figure 5B). HL60 cells cultured in serum-depleted medium also showed high ZGA sensitivity (67% TB+ death in serum-depleted medium with ZGA versus 9% in serum-depleted medium without ZGA) that was partially reversed by the addition of LDL (to 40% TB+). KG1a cells, however, were insensitive to ZGA even when cultured in serum-depleted medium (6% TB+ with ZGA versus 4% TB+ without ZGA). These data indicate that the toxicities of cholesterol synthesis inhibitors such as ZGA and mevastatin in NB4 and HL60 cells are reduced by cholesterol available from the ambient environment and that certain AMLs (eg, KG1a) may be less dependent on cholesterol for their survival.
Although a majority of adult patients with AML initially achieve complete remission with conventional chemotherapy, most eventually relapse and succumb to drug-resistant disease. Given this prevalence of drug-resistant AMLs, a number of workers have examined the potential antineoplastic effects of the cholesterol-lowering agents commonly known as "statins," either alone or as chemotherapy sensitizers. Two groups have shown that lovastatin33 and simvastatin34 can sensitize AML cell lines to cytarabine. Another group has demonstrated that lovastatin is toxic to AML cell lines and to primary AML cell samples but not to lymphocytic leukemias.13 We have previously shown that a subset of primary AML cell samples, but not normal myeloid cells, can be sensitized to cytarabine and/or daunorubicin by mevastatin.14 Because the mevalonate pathway inhibited by statins produces several by-products in addition to cholesterol, including the farnesyl pyrophosphate and geranylgeranyl pyrophosphate moieties necessary to isoprenylate Ras and other similarly modified membrane signaling proteins, many investigators have assumed that statin efficacy in AML and other malignancies is related to the inhibition of membrane protein isoprenylation. In this report, however, we present data to indicate that direct cholesterol modulation may also play a role in the efficacy of statins against AML. It has long been known that cholesterol metabolism is dysregulated in many malignancies, including AML, in which high rates of cholesterol import and/or synthesis have been documented.3,4 Leukemic cell lines selected for resistance to chemotherapy have also been found to contain elevated lipid levels.6 These findings suggest that increased cholesterol levels may serve to protect leukemic cells. We have previously demonstrated a similar concept in renal tubule cells that protect themselves from various ischemic and oxidative insults by dramatically increasing their cellular cholesterol content, thereby achieving a state of "acquired cytoresistance."22 We now document that some AML cell lines also respond to radiochemotherapeutic insults by significantly increasing cellular cholesterol content above constitutive levels. Certain primary AML cell samples manifest similar behavior after exposure to cytarabine and daunorubicin, with significantly greater increases in cellular cholesterol than that seen in similarly treated normal bone marrow cell samples. To further examine the potential role of cholesterol modulation in protecting certain AMLs against radiation or chemotherapy, we inhibited cholesterol synthesis at the level of squalene synthase, which is the rate-limiting enzyme at the final branch point in the mevalonate pathway leading to cholesterol synthesis.31,32 In this manner, we were able to disrupt cholesterol synthesis while minimizing interference with upstream portions of the mevalonate pathway that are responsible for the production of moieties such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate.1 We demonstrated that the squalene synthase inhibitor zaragozic acid A (ZGA) produced cell death only in the cell lines (ie, NB4 and HL60) that mounted cholesterol increments in response to radiotherapeutic or chemotherapeutic insults and that exhibited sensitivity to mevastatin. We subsequently showed that cotreatment of NB4 cells with ZGA and either cytarabine or radiation resulted in a marked attenuation of the cholesterol increment that would otherwise have occurred in these cells after exposure to cytarabine or radiation alone. At the same time, the addition of ZGA to cytarabine or radiation induced at least an additive toxicity in NB4 cells. This association of increased toxicity with the attenuation of cholesterol increments provides further credence for the concept of adaptive cholesterol responses as a cytoprotective mechanism in particular AMLs. One of the arguments that has been raised in the literature against a role for cholesterol modulation in the antineoplastic effects of statins has been the inability of exogenous squalene and free cholesterol to reduce lovastatin toxicity in NB4 cells.20 However, cells do not always efficiently incorporate free sterols, as was shown for K562 cells exposed to exogenous squalene and lanosterol.35 On the other hand, cells can efficiently obtain cholesterol from the ambient environment by receptor-mediated import of LDL.1 We have shown that treating NB4 cells with ZGA in a serum-depleted (and hence cholesterol-depleted) medium resulted in more than 70% toxicity within 24 hours, while the addition of LDL cholesterol (more than 95% purity) to these cultures reversed the toxicity of ZGA, further supporting the vital cytoprotective role of cellular cholesterol in certain AMLs. Our findings do not exclude the possibility that reduced isoprenylation may contribute to statin toxicity in particular AMLs but do highlight the possible importance of direct cholesterol modulation in new antileukemia therapies. Nonstatin drugs that reduce protective cellular cholesterol may be more desirable for eradicating cholesterol-dependent leukemias for several reasons. Some AMLs are apparently able to further up-regulate LDL receptor activity after treatment with statins,4 which could limit the ability of statins to decrease protective cellular cholesterol. In addition, statins apparently block the production of a mevalonate-derived Ras inhibitor that accumulates when the mevalonate pathway is instead blocked at a downstream step by a diphosphomevalonate decarboxylase inhibitor.36 Therefore, statin treatments could potentially favor the growth of tumor cells that are regulated by this inhibitor, whereas inhibition of cholesterol synthesis distal to diphosphomevalonate decarboxylase activity would not have this effect. Consistent with this idea, Hohl and his coworkers have reported that lovastatin can increase proliferation in a large number of primary leukemia cell samples.37 Squalene synthase inhibitors that block cholesterol biosynthesis at the final committed step of the mevalonate pathway are being tested for hypercholesterolemia indications,38,39 and our findings with ZGA suggest that squalene synthase inhibitors and other direct cholesterol-modulating agents should be rigorously tested as chemotherapy sensitizers in acute myeloid leukemia.
The authors thank Sasha Bidwell and Ali C. M. Johnson for providing excellent technical assistance and Irwin Bernstein and Shelly Heimfeld for providing cryopreserved marrow specimens.
Submitted July 31, 2002; accepted December 10, 2002.
Prepublished online as Blood First Edition Paper, December 27, 2002; DOI 10.1182/blood-2002-07-2283.
Supported by a Leukemia and Lymphoma Society Chuck Griffin Memorial Translation Research Award (D.E.B.) and National Institutes of Health grants UO1-CA32102 (Southwest Oncology Group/C.L.W.), CA18029 (F.R.A.), DK38432 and DK54200 (R.A.Z.), U10-CA13539 (Children's Cancer Group AML Reference Laboratory), and T32-HL07093 (H.Y.L.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Deborah E. Banker, Fred Hutchinson Cancer Research Center, Clinical Research Division, D1-100, PO Box 19024, Seattle, WA 98109-1024; e-mail: dbanker{at}fhcrc.org.
1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430[CrossRef][Medline] [Order article via Infotrieve]. 2. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med. 1998;104:2S-5S[Medline] [Order article via Infotrieve].
3.
Rudling M, Gafvels M, Parini P, Gahrton G, Angelin B.
Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation.
Am J Pathol.
1998;153:1923-1935
4.
Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H.
Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells.
Blood.
1994;84:2689-2698 5. Maksumova L, Ohnishi K, Muratkhodjaev F, et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia. 2000;14:1444-1450[CrossRef][Medline] [Order article via Infotrieve]. 6. May GL, Wright LC, Dyne M, Mackinnon WB, Fox RM, Mountford CE. Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts. Int J Cancer. 1988;42:728-733[Medline] [Order article via Infotrieve]. 7. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest. 1985;76:1748-1754[Medline] [Order article via Infotrieve]. 8. Prasanna P, Thibault A, Liu L, Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and phenylacetate against human glioma cells. J Neurochem. 1996;66:710-716[Medline] [Order article via Infotrieve].
9.
Dimitroulakos J, Ye LY, Benzaquen M, et al.
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Clin Cancer Res.
2001;7:158-167 10. Muller C, Bockhorn AG, Klusmeier S, et al. Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol. 1998;12:717-723[Medline] [Order article via Infotrieve]. 11. Clutterbuck RD, Millar BC, Powles RL, et al. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol. 1998;102:522-527[CrossRef][Medline] [Order article via Infotrieve]. 12. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483-491[Abstract].
13.
Dimitroulakos J, Nohynek D, Backway KL, et al.
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach.
Blood.
1999;93:1308-1318 14. Stirewalt DL, Appelbaum FR, Willman CL, Banker DE. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res. 2003;27:135-147.
15.
Beaupre DM, Kurzrock R.
RAS and leukemia: from basic mechanisms to gene-directed therapy.
J Clin Oncol.
1999;17:1071-1079 16. Weijzen S, Velders MP, Kast WM. Modulation of the immune response and tumor growth by activated Ras. Leukemia. 1999;13:502-513[CrossRef][Medline] [Order article via Infotrieve].
17.
Barrington RE, Subler MA, Rands E, et al.
A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
Mol Cell Biol.
1998;18:85-92
18.
Mangues R, Corral T, Kohl NE, et al.
Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Cancer Res.
1998;58:1253-1259
19.
Beaupre DM, Talpaz M, Marini FC III, et al.
Autocrine interleukin-1- 20. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia. 2001;15:1398-1407[CrossRef][Medline] [Order article via Infotrieve].
21.
Sinensky M, Beck LA, Leonard S, Evans R.
Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis.
J Biol Chem.
1990;265:19937-19941 22. Zager RA, Burkhart KM, Johnson AC, Sacks BM. Increased proximal tubular cholesterol content: implications for cell injury and "acquired cytoresistance." Kidney Int. 1999;56:1788-1797[CrossRef][Medline] [Order article via Infotrieve].
23.
Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R.
NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3).
Blood.
1991;77:1080-1086 24. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature. 1977;270:347-349[CrossRef][Medline] [Order article via Infotrieve].
25.
Skubitz KM, Zhen Y, August JT.
A human granulocyte-specific antigen characterized by use of monoclonal antibodies.
Blood.
1983;61:19-26
26.
Koeffler HP, Billing R, Lusis AJ, Sparkes R, Golde DW.
An undifferentiated variant derived from the human acute myelogenous leukemia cell line (KG-1).
Blood.
1980;56:265-273
27.
Banker DE, Groudine M, Norwood T, Appelbaum FR.
Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.
Blood.
1997;89:243-255
28.
Zager RA, Kalhorn TF.
Changes in free and esterified cholesterol: hallmarks of acute renal tubular injury and acquired cytoresistance.
Am J Pathol.
2000;157:1007-1016 29. Slater EE, MacDonald JS. Mechanism of action and biological profile of HMG CoA reductase inhibitors: a new therapeutic alternative. Drugs. 1988;36(suppl 3):72-82[Medline] [Order article via Infotrieve]. 30. Zager RA. Plasma membrane cholesterol: a critical determinant of cellular energetics and tubular resistance to attack. Kidney Int. 2000;58:193-205[CrossRef][Medline] [Order article via Infotrieve].
31.
Bergstrom JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG.
Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase.
Proc Natl Acad Sci U S A.
1993;90:80-84 32. Amin D, Rutledge RZ, Needle SN, et al. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhi | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Top
Abstract
Introduction
production in leukemia: evidence for the involvement of mutated RAS.
Cancer Res.
1999;59:2971-2980